Restless Legs Syndrome - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 44
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R85FE7F9AF2EN
Leaflet:

Download PDF Leaflet

Restless Legs Syndrome - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Restless Legs Syndrome - Pipeline Review, H2 2016’, provides an overview of the Restless Legs Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
  • The report reviews pipeline therapeutics for Restless Legs Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Restless Legs Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Restless Legs Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Restless Legs Syndrome
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome Overview
Therapeutics Development
Pipeline Products for Restless Legs Syndrome - Overview
Restless Legs Syndrome - Therapeutics under Development by Companies
Restless Legs Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Restless Legs Syndrome - Products under Development by Companies
Restless Legs Syndrome - Companies Involved in Therapeutics Development
Alexza Pharmaceuticals, Inc.
Galenica Ltd.
Hisamitsu Pharmaceutical Co., Inc.
Ligand Pharmaceuticals, Inc.
Mundipharma International Ltd
Omeros Corporation
Restless Legs Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aplindore fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropinirole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restless Legs Syndrome - Dormant Projects
Restless Legs Syndrome - Discontinued Products
Restless Legs Syndrome - Product Development Milestones
Featured News & Press Releases
May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs
Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome
Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome
Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Restless Legs Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
Restless Legs Syndrome - Pipeline by Galenica Ltd., H2 2016
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016
Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H2 2016
Restless Legs Syndrome - Pipeline by Omeros Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Restless Legs Syndrome - Dormant Projects, H2 2016
Restless Legs Syndrome - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Restless Legs Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Alexza Pharmaceuticals, Inc.
Galenica Ltd.
Hisamitsu Pharmaceutical Co., Inc.
Ligand Pharmaceuticals, Inc.
Mundipharma International Ltd
Omeros Corporation
Skip to top


Ask Your Question

Restless Legs Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: